Meeting report: 3rd Neuroblastoma Research Symposium, Liverpool, 6–7th November, 2013. Issue 9 (7th May 2014)

• Record Type: Journal Article
• Authors: Bell, Emma; Chen, Lindi; Viprey, Virginie F.; Blanchard, Guy B.
• Is Part Of: Pediatric blood & cancer. Volume 61:Issue 9(2014:Sep.)
• Page Start: 1711
• Page End: 1713
• Publication Date: 2014-05-07
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25087
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25087-sec-0001" sec-type="section"> <p>Neuroblastoma is an embryonal malignancy of the developing neural crest. Despite improvements in treatment, prognoses remain dire for patients with high‐risk disease. Interest in this enigmatic cancer has led to a rapidly changing research landscape and we report on the recent advances in four themes that were discussed at the 3rd Neuroblastoma Research Symposium: (1) The epigenetic signature of neuroblastoma and the epigenetic control of tumour development, (2) novel approaches to targeting MYCN, (3) valuable <italic>in vivo</italic> modelling and (4) improving differentiation therapies based on a knowledge of normal sympathetic neuron development. Through lively discussion, the development of combined therapies with synergistic effects for which we have a good mechanistic understanding emerged as offering greatest promise. Drug synergies enhance efficacy but also specificity, the latter crucial for reducing long‐term side effects in young children. Pediatr Blood Cancer 2014;61:1711–1713. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>